CoChat
Sign Up
Cited by 138Viral Infections and Immunology ResearchInfectious Encephalopathies and EncephalitisLiterature Analysis and Criticism

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis

ABZUG, MARK J., CLOUD, GRETCHEN, BRADLEY, JOHN, SÁNCHEZ, PABLO J., ROMERO, JOSÉ, POWELL, DWIGHT, LEPOW, MARTHA, MANI, CHITRA, CAPPARELLI, EDMUND V., BLOUNT, SHARON, LAKEMAN, FRED, WHITLEY, RICHARD J., KIMBERLIN, DAVID W.·2003·The Pediatric Infectious Disease Journal
DOI 10.1097/01.inf.0000059765.92623.70
Open this paper in CoChat — free account

Abstract

Background Enterovirus (EV) meningitis is common in infants and may have neurologic complications. Treatment of older children and adults with pleconaril has been associated with reduced severity and duration of symptoms. This study evaluated the pharmacokinetics, safety and efficacy of pleconaril in infants with EV meningitis. Methods Infants Results Of 21 evaluable subjects 20 were confirmed with EV infection (12 pleconaril, 8 placebo). Among pleconaril-treated subjects 26 of 29 peak and trough pleconaril levels exceeded the 90% inhibitory concentration for EVs. A median 3.5-fold drug accumulation occurred between Days 2 and 7. Pleconaril was well-tolerated, although twice as many adverse events occurred per subject in the pleconaril group. Serial cultures from the oropharynx, rectum and serum had low yield ( or =50%) persisting through Day 14. No significant differences in duration of positivity by culture or PCR, hospitalization or symptoms were detected between groups. Conclusions The dose of pleconaril studied provided sufficient plasma levels and was well-tolerated; however, drug accumulation was evident. The low yields of serial viral cultures, relatively short and benign clinical courses and the small number of subjects enrolled precluded demonstration of efficacy. If this medication is to be prescribed in infants, surveillance for toxicity related to drug accumulation will be necessary.

Overview

Integrity signals

Registry

Crossref · 10.1097/01.inf.0000059765.92623.70

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

Sorted by citations

See all 138

Related

See all

Metadata

Authors
ABZUG, M. J., CLOUD, G., BRADLEY, J., SÁNCHEZ, P. J., ROMERO, J., POWELL, D., LEPOW, M., MANI, C., CAPPARELLI, E. V., BLOUNT, S., LAKEMAN, F., WHITLEY, R. J., & KIMBERLIN, D. W.
Affiliations
University of Colorado Anschutz (US)
ORCID
Venue
The Pediatric Infectious Disease Journal
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2003-04
Volume
22
Issue
4
Pages
335-340
ISSN
0891-3668 (ISSN-L)
DOI
10.1097/01.inf.0000059765.92623.70
OpenAlex
W2054734620
Cited by
138
References
15
Citations by year
2026: 1 · 2025: 7 · 2024: 5 · 2023: 6 · 2022: 4 · 2021: 6 · 2020: 2 · 2019: 6 · 2018: 5 · 2017: 7 · 2016: 10 · 2015: 13 · 2014: 11 · 2013: 4 · 2012: 5
FWCI
4.18
Type
journal article
Language
en
Open access
closed
Locations
  • The Pediatric Infectious Disease Journal (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (n01ai062554-008, n01ai015113-000)
  • National Institute of Allergy and Infectious Diseases (N01-AI -15113, N01 AI 62554)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
  • Health Sciences › Medicine › Infectious Diseases › Infectious Encephalopathies and Encephalitis
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Literature Analysis and Criticism
Keywords
pleconaril, enterovirus meningitis, infants, pharmacokinetics, drug accumulation, antiviral therapy, PCR detection, drug safety, adverse events, neurological complications
MeSH terms
Administration, Oral, Biological Availability, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Enterovirus Infections, Female, Follow-Up Studies, Humans, Infant, Male, Meningitis, Viral, Oxadiazoles, Oxazoles, Probability, Reference Values, Severity of Illness Index, Treatment Outcome, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review